When was Boundless Bio founded?

Boundless Bio was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Boundless Bio located?

Boundless Bio is headquartered in San Diego, United States. It is registered at San Diego, California.

Who is the current CEO of Boundless Bio?

Zachary Hornby of Boundless Bio.

How many employees does Boundless Bio have?

As of Aug 31, 2026, the latest employee count at Boundless Bio is 34.

Is Boundless Bio a funded company?

Boundless Bio is a funded company, having raised a total of $252M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 19, 2019.

When was the latest funding round of Boundless Bio?

Boundless Bio's latest funding was a $***** Series C round on May 16, 2023, with participation from 16 investors.

Where does Boundless Bio rank among its competitors?

Boundless Bio ranks 8th amongst 313 active competitors, of which 112 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was FoRx Therapeutics, which secured $50M in Dec, 2025.

Who are the top competitors of Boundless Bio?

Boundless Bio's top competitors include Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics. Among them, FoRx Therapeutics secured the most recent funding round in December, 2025.

Boundless Bio - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics for cancer by targeting ecDNA. The company focuses on interrogating extrachromosomal DNA biology to deliver transformative therapies to patients with intractable oncogene amplified cancers.

Website: boundlessbio.com
Social
Email ID: *****@boundlessbio.com
Phone Number: +1 **********
Registered Address: San Diego, California

Key Metrics

Founded Year

2018

Location

San Diego, United States

Stage

Public

Total Funding

$252M in 4 rounds

Latest Funding Round

Series C, May 16, 2023, $*****

Investors

RA Capital Management & 20 more

Ranked

8^th among 313 active competitors

Employee Count

34 as on Aug 31, 2026

Similar Companies

Abcellera Biologics & 402 more

Exit Details

Public

View Boundless Bio's full profile

Boundless Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Boundless Bio, Inc. CIN: 830751369 , United States, Active	Dec 31, 2017	-	29 (As on Dec 31, 2020)	-

Boundless Bio got listed on Mar 28, 2024.

Click here to take a look at Boundless Bio's IPO in detail

Boundless Bio has raised a total funding of $252M over 4 rounds. Its first funding round was on Sep 19, 2019. Its latest funding round was a Series C round on May 16, 2023 for $*****. 16 investors participated in its latest round. Boundless Bio has 21 institutional investors.

Here is the list of recent funding rounds of Boundless Bio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 16, 2023	1033203	Series C	7650218	6469382	6914767	6890063
Jun 16, 2022	9962657	Grant (prize money)	4977921	9277563	5194678	National Cancer Institute & 1 more
Apr 28, 2021	3340078	Series B	1813967	1714023	Nextech Invest & 1 more	Wellington & 11 more

Access funding benchmarks and valuations. Sign up today!

View details of Boundless Bio's funding rounds and investors

The founders of Boundless Bio is Jonathan Lim.

Here are the details of Boundless Bio's key team members:

Jonathan Lim: Co-Founder of Boundless Bio.
Zachary Hornby: CEO of Boundless Bio.

View details of Boundless Bio's Founder profiles and Board Members

Boundless Bio's employee count trend

Boundless Bio has 34 employees as of Aug 26. Here is Boundless Bio's employee count trend over the years:

Uncover Boundless Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Boundless Bio include Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics. Here is the list of Top 10 competitors of Boundless Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
2nd	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
3rd	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, Novartis & 9 others	70/100
4th	Beijing Jiakesi drug development 2015, Beijing (China), Public	Developer of small molecule based therapeutics for cancer treatment	$55M	Qiming Venture Partners, Lilly Asia Ventures ... & 3 others	67/100
5th	Lyell Immunopharma 2018, San Francisco (United States), Public	Developer of CAR- T therapy for cancer treatment	$493M	Sahsen Ventures, GSK & 5 others	63/100
6th	ABL Bio 2016, Seongnam-si (South Korea), Public	Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases	$65M	QUAD, Hana Financial Group & 7 others	63/100
7th	Black Diamond Therapeutics 2017, Cambridge (United States), Public	Developing MasterKey therapies to defeat cancer resistance and improve patient lives	$207M	Boxer Capital, RA Capital Management & 19 others	61/100
8th	Boundless Bio 2018, San Diego (United States), Public	Developer of therapeutics for cancer by targeting ecDNA	$252M	Boxer Capital, Fidelity Investments & 19 others	57/100
9th	FoRx Therapeutics 2019, Basel (Switzerland), Series A	Developer of compounds for treating cancer	$60.8M	Omega Funds, Novartis Venture Fund & 5 others	61/100
10th	Nanobiotix 2003, Paris (France), Public	Developer of nanotherapeutics designed to enhance cancer treatment via radioenhancement	$11M	European Investment Bank, Masseran Gestion ... & 10 others	60/100